Home › Compare › NDCVF vs ABBV
NDCVF yields 13.11% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 6
Combined, NDCVF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of NDCVF + ABBV for your $10,000?
Nordic Semiconductor ASA, a fabless semiconductor company, designs, develops, markets, and sells integrated circuits and related solutions for short-and long-range wireless applications in Europe, the Americas, and the Asia/Pacific. It offers ultra-low power components; and develops low power cellular IoT. The company also provides Bluetooth 5 solutions; low power cellular devices for the IoT; and Bluetooth 5.1 solutions for direction finding applications. In addition, it offers Zigbee 3.0 IoT solutions; Thread solution for low-power devices; nRF9160 system-in-package; nRF52 and nRF51 series system-on-chips, as well as nRF591, nRF53, nRF52, and nRF51 series software development kits; ANT, a proprietary ultra-low power wireless solution for battery operated products; and application specific integrated circuits and related consulting services. Further, the company provides software for system development, communication stacks, and application layer software, as well as development tools for desktops. Its products are used in various applications, such as audio, automotive, beacon, computer peripherals, drug delivery, patient monitoring and alerts, smart home, healthcare, connected health and home, education, industrial automation, LED lighting, logistics/asset tracking, transportation, retail and payment, sports and fitness, toys and gaming, virtual reality and augmented reality products, wireless PC peripherals, mobile phone accessories, and consumer electronics, as well as wearables, including connected watches, jewelry, proximity tags, and smart clothes and apparels. The company was founded in 1983 and is headquartered in Trondheim, Norway.
Full NDCVF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.